Ceftolozane/tazobactam positive data for UTI and cIAI infections - Cubist
Cubist Pharmaceuticals, Inc. has announced the first detailed results from positive pivotal Phase III clinical trials of its antibiotic candidate ceftolozane/tazobactam in development to treat serious infections including complicated Urinary Tract Infections (cUTI) and complicated Intra-Abdominal Infections (cIAI). Results will be presented at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Barcelona May 10 - 13. These new data include additional details on ceftolozane/tazobactam�s clinical cure and/or microbiological eradication rates, which met or exceeded pre-specified FDA and European Medicines Agency (EMA) non-inferiority margins, as well as details on the overall safety profile. Additionally, for the first time Cubist is presenting data on microbiological eradication of key problematic Gram-negative pathogens, including Pseudomonas aeruginosa and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E. coli) and Klebsiella pneumoniae.
Microbiological eradication rates for ceftolozane/tazobactam were 84% - 100% in these pathogens across the cUTI and cIAI clinical trials.